Literature DB >> 9795772

Are there unique autoantigens triggering autoimmune diseases?

J F Bach1, S Koutouzov, P M van Endert.   

Abstract

Using three reference disease models--insulin-dependent diabetes mellitus (IDDM) as a prototype of T-cell mediated organ-specific autoimmune disease, myasthenia gravis (MG) as a prototype of autoantibody-mediated organ-specific autoimmune disease and systemic lupus erythematosus (SLE) as a prototype of non-organ-specific autoimmune disease--we have reached several conclusions: 1) All three diseases are associated with the presence of multiple autoantibodies and/or autoreactive T cells that recognize a large number of antigenic molecules. The apparent predominant role of certain antibodies in some diseases could relate to their functional properties such as acetylcholine receptor (AChR) blockade for anti-AChR autoantibodies in MG or anti-dsDNA in SLE. 2) Major target antigens are clustered in the target cell affected by organ-specific autoimmune diseases: beta cells in IDDM, striated-muscle cells in MG, or apoptotic cells in the case of SLE. 3) Antibodies and T cells recognize multiple epitopes in these molecules. 4) The most evident explanation for the observed clustering and diversity is autoantigen spreading. Spreading probably involves T cells secreting proinflammatory cytokines but also possibly antibodies as in the case of nucleosome autoantibodies in SLE. 5) The counterpart of antigen spreading is bystander suppression in which regulatory cytokines deviate the immune response towards a protective response. 6) The mechanisms underlying the initiation of the autoimmune response and antigen spreading are still undetermined. They could imply a direct abnormality of the target cell in the case of organ-specific autoimmune diseases (e.g. infection with a virus showing a selective tropism for the target cell in organ-specific autoimmune diseases, or loss of physiological regulation of major histocompatibility complex molecule expression) or could be consequence of a ubiquitous cell abnormality such as increased apoptosis in SLE. The respective roles of genetic and environmental factors in these triggering events remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9795772     DOI: 10.1111/j.1600-065x.1998.tb01216.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  17 in total

Review 1.  New concepts of the etiopathogenesis and treatment of insulin-dependent diabetes mellitus.

Authors:  J F Bach
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  T cell response to Hu-D peptides in patients with anti-Hu syndrome.

Authors:  A Rousseau; B Benyahia; J Dalmau; F Connan; J-G Guillet; J-Y Delattre; J Choppin
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

3.  Immunotherapy after recent-onset type 1 diabetes: combinatorial treatment for achieving long-term remission in humans?

Authors:  Damien Bresson; Matthias von Herrath
Journal:  Rev Diabet Stud       Date:  2004-11-10

4.  Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab.

Authors:  M Hardy-Werbin; O Arpí; A Taus; P Rocha; D Joseph-Pietras; L Nolan; S Danson; R Griffiths; M Lopez-Botet; A Rovira; J Albanell; C H Ottensmeier; E Arriola
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

Review 5.  Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: A B-cell immunomics approach.

Authors:  Christopher M Tipton; Jennifer R Hom; Christopher F Fucile; Alexander F Rosenberg; Inaki Sanz
Journal:  Immunol Rev       Date:  2018-07       Impact factor: 12.988

6.  Antigen is required for maturation and activation of pathogenic anti-DNA antibodies and systemic inflammation.

Authors:  Jeganathan Venkatesh; Hajime Yoshifuji; Daisuke Kawabata; Prameladevi Chinnasamy; Anfisa Stanevsky; Christine M Grimaldi; Joel Cohen-Solal; Betty Diamond
Journal:  J Immunol       Date:  2011-03-28       Impact factor: 5.422

Review 7.  Antigen-specific immunotherapies in rheumatic diseases.

Authors:  Judit Pozsgay; Zoltán Szekanecz; Gabriella Sármay
Journal:  Nat Rev Rheumatol       Date:  2017-07-13       Impact factor: 20.543

8.  In vivo tolerance breakdown with dendritic cells pulsed with U1A protein in non-autoimmune mice: the induction of a high level of autoantibodies but not renal pathological changes.

Authors:  Jau-Ling Suen; Ya-Hui Chuang; Bor-Luen Chiang
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

9.  Mycoplasma infection induces a scleroderma-like centrosome autoantibody response in mice.

Authors:  I Gavanescu; G Pihan; E Halilovic; E Szomolanyi-Tsuda; R M Welsh; S Doxsey
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

10.  Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus.

Authors:  M Amagai; K Tsunoda; H Suzuki; K Nishifuji; S Koyasu; T Nishikawa
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.